$FibroGen(FGEN.US)$ NEWS FibroGen Reports First Quarter 2024 Financial Results FibroGen, Inc. (NASDAQ: FGEN) reported strong financial results for Q1 2024, showing a 55% year-over-year net revenue growth driven by roxadustat sales in China and one-time revenue from the termination of the US/RoW AstraZeneca agreement. The company has a healthy cash balance of $214.7 million, ensuring financial stability till 2026. 55% year-over-year net revenue growth in Q1 2024. Robust roxadustat sales in China ...
$FibroGen(FGEN.US)$ NEWS FIBROGEN ANNOUNCES CLINICAL DATA FROM DOSE ESCALATION PHASE 1B STUDY OF FG-3246 (FOR46) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WILL BE PRESENTED AT THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
Dr. Adib's appointment, with his vast oncology drug development experience, is viewed as a crucial step to speed up FibroGen's oncology pipeline and deliver innovative cancer treatments. His leadership is anticipated to aid the company's ongoing and future clinical development activities.
Analysts are more negative on FibroGen post-earnings, cutting revenue estimates and predicting higher losses. Despite projected revenue growth, FibroGen's expected growth is slower than the industry. The consensus price target dropped significantly, showing analysts' lack of confidence in the latest results and a lower future valuation estimate for FibroGen.
FibroGen股票討論區
📊⚡️📊
NEWS
FibroGen Reports First Quarter 2024 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) reported strong financial results for Q1 2024, showing a 55% year-over-year net revenue growth driven by roxadustat sales in China and one-time revenue from the termination of the US/RoW AstraZeneca agreement. The company has a healthy cash balance of $214.7 million, ensuring financial stability till 2026.
55% year-over-year net revenue growth in Q1 2024.
Robust roxadustat sales in China ...
NEWS
FIBROGEN ANNOUNCES CLINICAL DATA FROM DOSE ESCALATION PHASE 1B STUDY OF FG-3246 (FOR46) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WILL BE PRESENTED AT THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
$CG Oncology(CGON.US)$ Phase 3
$美國聯合醫療(UTHR.US)$ Phase 3
$美國聯合醫療(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$烏龍製藥(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...
here are 6 cancer readouts to watch this quarter:
$ImmunityBio(IBRX.US)$ : Anktiva ▻ PDUFA ▻ Bladder CA
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib ▻ PDUFA ▻ Glioma
$GlycoMimetics(GLYC.US)$ : Uproleselan ▻ Ph3 ▻ AML
$FibroGen(FGEN.US)$ : Pamrevlumab ▻ Ph3 ▻ Pancreatic CA
$Viracta Therapeutics(VIRX.US)$ : Nana-val ▻ Ph3 ▻ Lymphoma
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$和黃醫藥(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$烏龍製藥(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...
暫無評論